

**This week in therapeutics**

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Huntington's disease (HD)	Huntingtin (HTT); ataxin 3 (ATXN3)	<i>In vitro</i> and mouse studies identified peptoids that bind polyglutamate repeats and could help treat HD. A screen of 60,000 peptoids, which are oligomers of N-substituted glycines, identified a lead peptoid that bound to HTT and ATXN3 proteins carrying expanded polyglutamate repeats. In a mouse model of HD, brain infusion of the peptoid decreased HTT aggregation and improved motor performance compared with vehicle control. Next steps include increasing peptoid blood brain barrier permeability.	Patent application filed; available for licensing	Chen, X. <i>et al. Chem. Biol.</i> ; published online Sept. 23, 2011; doi:10.1016/j.chembiol.2011.06.010 <b>Contact:</b> Ilya Bezprozvanny, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: <a href="mailto:Ilya.Bezprozvanny@UTSouthwestern.edu">Ilya.Bezprozvanny@UTSouthwestern.edu</a>
<b>SciBX 4(40); doi:10.1038/scibx.2011.1124</b> <b>Published online Oct. 13, 2011</b>				